Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer

Joan Rou En Choo, Chee Seng Tan, Ross A. Soo

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)


The treatment of lung cancer has changed dramatically with the development of tyrosine kinase inhibitors (TKIs) that target sensitizing somatic mutations of the epidermal growth factor receptor (EGFR). Despite remarkable initial responses, patients eventually develop progressive disease, with the most common cause of resistance to first-line EGFR TKIs being the acquired T790M mutation. Various third-generation EGFR TKIs have been developed to specifically target this acquired mutation, of which osimertinib is currently the only approved agent. In addition, the eagerly anticipated data from the FLAURA study recently found improved efficacy with increased progression-free survival (PFS) with osimertinib compared to standard of care first-generation EGFR TKIs in the first-line setting. Of note, osimertinib has also demonstrated promising efficacy in patients with known brain metastases. However, as patients invariably develop resistance during treatment with osimertinib, most commonly with the development of triple mutated EGFR (sensitizing mutations/T790M/C797S), which is resistant to all existing EGFR TKIs, efforts are currently ongoing to develop new strategies or novel compounds to specifically target this resistance mechanism.

Original languageEnglish
Pages (from-to)141-156
Number of pages16
JournalTargeted Oncology
Issue number2
Publication statusPublished - 1 Apr 2018


Dive into the research topics of 'Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this